<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oseltamivir: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oseltamivir: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Oseltamivir: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10931" href="/d/html/10931.html" rel="external">see "Oseltamivir: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12662" href="/d/html/12662.html" rel="external">see "Oseltamivir: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F204115"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tamiflu</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867772"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP Oseltamivir;</li>
<li>MAR-Oseltamivir;</li>
<li>MINT-Oseltamivir;</li>
<li>NAT-Oseltamivir;</li>
<li>Tamiflu</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F204138"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiviral Agent;</li>
<li>
                        Neuraminidase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F204118"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8cef53-c206-4ec0-8c9a-97d26dbfafc9">Influenza, seasonal, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, seasonal, prophylaxis: Oral:</b> 75 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Postexposure prophylaxis:</b>
<b>Note:</b> Consider use in patients at <i>very</i> high risk for influenza complications (eg, patients who are severely immunocompromised) who have had close contact within the past 48 hours with a person with confirmed or suspected influenza during that person's infectious period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30834445'])">Ref</a></span>). Some experts also suggest use in patients at high risk (see <b>
<i>Persons at increased risk for complications</i></b> below) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Zachary.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Zachary.2019'])">Ref</a></span>). Continue for 1 week after last exposure (if previously vaccinated) or 2 weeks (if unvaccinated) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Institutional outbreaks:</b></i> Recommended for <b>all</b> residents regardless of vaccination status and continued for at least 2 weeks and 1 week after the last known case (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-30834445'])">Ref</a></span>). Consider prophylaxis in employees, depending on vaccination status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30834445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Preexposure prophylaxis:</b> Only during widespread outbreaks for persons at very high risk for influenza complications (eg, patients who are severely immunocompromised) not protected by vaccination. Continue for the duration of influenza activity or for 2 weeks following vaccination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-30834445'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8e42eebf-1cc9-4d9c-8452-1459db020923">Influenza, seasonal, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, seasonal, treatment: Oral:</b> 75 mg twice daily. <b>Note: </b>Higher doses (150 mg twice daily) are <b>not </b>currently recommended even in severely ill or immunocompromised patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20159892','lexi-content-ref-CDC.1','lexi-content-ref-24046309','lexi-content-ref-23723457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20159892','lexi-content-ref-CDC.1','lexi-content-ref-24046309','lexi-content-ref-23723457'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Timing of initiation/target population: </i></b>In patients with severe, complicated, or progressive illness; hospitalized patients; or those at increased risk for complications (see <b>
<i>Persons at increased risk for complications </i></b>below), initiate treatment as soon as possible even if &gt;48 hours have elapsed since illness onset and do <b>not</b> delay for laboratory confirmation. For symptomatic outpatients with mild illness not at increased risk for complications, treatment can be considered only if it can be initiated ≤48 hours following illness onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-30834445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Duration of therapy</i>
<i>:</i></b> Usual duration: 5 days; a longer duration may be considered in patients who are severely ill or immunocompromised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-30834445'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="43825acb-3146-40c6-bbbc-4b8d476451ea">Influenza A, avian, postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza A, avian, postexposure prophylaxis (off-label use): Oral:</b> 75 mg twice daily for 5 days (from the last known exposure) if exposure was time-limited and not ongoing <b>or</b> 10 days if exposure is likely to be ongoing (eg, household setting) due to potential for prolonged infectiousness in the case-patient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2016a','lexi-content-ref-CDC.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2016a','lexi-content-ref-CDC.2017'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0983fe10-85d8-420f-befa-4e9f5884fafb">Influenza A, avian, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza A, avian, treatment (off-label use): Oral:</b> 75 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2016b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2016b'])">Ref</a></span>). <b>Note: </b>Higher doses (150 mg twice daily) are <b>not</b> currently recommended even in severely ill or immunocompromised patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20159892','lexi-content-ref-CDC.2016b','lexi-content-ref-29648602']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20159892','lexi-content-ref-CDC.2016b','lexi-content-ref-29648602'])">Ref</a></span>). Initiate <b>as soon as possible</b>, even if &gt;48 hours have elapsed since illness onset. Do <b>not </b>delay treatment while awaiting lab results. The usual duration is 5 days, but consider longer courses (eg, 10 days) for severely ill hospitalized patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2016b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2016b'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note:</b>
<i>Persons at increased risk for complications:</i> Adults ≥65 years of age, people who are pregnant or postpartum (within 2 weeks after delivery), residents of long-term care facilities, non-Hispanic Black persons, Hispanic or Latino persons, American Indians and Alaska natives, persons with BMI ≥40 kg/m<sup>2</sup> and individuals with certain chronic medical conditions (eg, pulmonary, cardiovascular, endocrine [eg, diabetes mellitus], renal, hepatic, hematologic, metabolic, neurologic, HIV, malignancy) or those receiving immunosuppressive medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>).</p></div>
<div class="block dora drugH1Div" id="F50991240"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Oseltamivir Dose Adjustments in Altered Kidney Function<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl</p></th>
<th align="center">
<p style="text-indent:0em;">
<b>If the usual indication-specific dose is 75 mg once daily (eg, seasonal influenza prophylaxis)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>If the usual indication-specific dose is 75 mg twice daily (eg, seasonal influenza treatment)</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>References (unless otherwise specified): Kamal 2015a; manufacturer’s labeling.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Jones 2021.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Expert opinion.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">≥60 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;30 to &lt;60 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">30 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">75 mg × 1 dose,<sup>b</sup> then 30 mg twice daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;10 to 30 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">30 mg every other day</p></td>
<td align="center">
<p style="text-indent:0em;">30 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≤10 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">30 mg once weekly<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;">30 mg every other day<sup>c</sup></p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Influenza, seasonal, treatment: There are no clinical or pharmacokinetic data available (has not been studied); however, a dose of 75 mg twice daily (up to 150 mg twice daily) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (~50%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20625883']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20625883'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Influenza, seasonal, treatment: 30 mg immediately and then 30 mg after every hemodialysis session for at least 5 days. <b>Note:</b> Assumes 3 hemodialysis sessions in the 5-day period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26282419','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26282419','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Influenza, seasonal, prophylaxis: 30 mg immediately and then 30 mg after every other hemodialysis session for the recommended prophylaxis duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26282419','lexi-content-ref-16799169','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26282419','lexi-content-ref-16799169','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Influenza, seasonal, treatment: 75 mg immediately as a single dose (single dose provides a 5-day duration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25289522','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25289522','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Influenza, seasonal, prophylaxis: 30 mg immediately and then 30 mg once weekly for the recommended prophylaxis duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16799169','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16799169','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour), unless otherwise noted. Close monitoring of response and adverse reactions (eg, neuropsychiatric) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">Influenza, seasonal, treatment: 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23208833','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23208833','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neuropsychiatric) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">Influenza, seasonal, treatment:</p>
<p style="text-indent:-2em;margin-left:8em;">PIRRT days: 75 mg once daily; administer dose after PIRRT session when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Non-PIRRT days: Dose as for CrCl ≤10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988484"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild-to-moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Severe impairment: No dosage adjustment provided in manufacturer’s labeling (has not been studied).</p></div>
<div class="block doo drugH1Div" id="F21674739"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, or 3 obesity (BMI ≥30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No dosage adjustment is necessary; refer to adult dosing for indication-specific doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26810861','lexi-content-ref-24366750','lexi-content-ref-21930881','lexi-content-ref-21700623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26810861','lexi-content-ref-24366750','lexi-content-ref-21930881','lexi-content-ref-21700623'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rationale for recommendations:</b> A study evaluating oseltamivir pharmacokinetics in patients with BMI ≥40 kg/m<sup>2</sup> found that apparent clearance was poorly correlated with body weight for both oseltamivir and oseltamivir carboxylate (active metabolite), and pharmacokinetic parameters were similar to those seen in normal-weight subjects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21930881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21930881'])">Ref</a></span>). Pharmacokinetic studies comparing obese (BMI ≥30 kg/m<sup>2</sup>) and nonobese subjects showed a decrease in systemic exposure of oseltamivir in subjects with obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24366750','lexi-content-ref-21700623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24366750','lexi-content-ref-21700623'])">Ref</a></span>); however, systemic exposure of oseltamivir carboxylate was similar (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26810861','lexi-content-ref-24366750','lexi-content-ref-21700623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26810861','lexi-content-ref-24366750','lexi-content-ref-21700623'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F204119"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F204130"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12662" href="/d/html/12662.html" rel="external">see "Oseltamivir: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1eb6edd9-fc37-44a9-87c3-ceaeb3c4c278">Influenza, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Clinical benefit is greatest if initiated within 48 hours. In patients with severe, complicated, or progressive illness, hospitalized patients, or those at increased risk for complications (see "Use" for details), initiate treatment as soon as possible even if &gt;48 hours have elapsed since illness onset and do not delay for laboratory confirmation. For symptomatic outpatients with mild illness not at increased risk for complications, treatment can be considered if it can be initiated ≤48 hours following illness onset. Usual duration of therapy is 5 days; a longer duration can be considered in severely ill or immunocompromised patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≤8 months: Oral: 3 mg/kg/dose twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34493538','lexi-content-ref-CDC.2','lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34493538','lexi-content-ref-CDC.2','lexi-content-ref-30834445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥9 months: Oral: 3.5 mg/kg/dose twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34493538','lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34493538','lexi-content-ref-30834445'])">Ref</a></span>); some experts still recommend manufacturer labeled dosing of 3 mg/kg/dose twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-30834445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">≤15 kg: Oral: 30 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;15 to 23 kg: Oral: 45 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;23 to 40 kg: Oral: 60 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: Oral: 75 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1627ce8d-90b5-41c4-a80f-50628f2cc1e2">Influenza, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, prophylaxis: Note:</b> Recommendations for patient selection for prophylaxis are variable. Duration of chemoprophylaxis varies with exposure or outbreak type, influenza vaccination status, presence of immunosuppression, and risk of severe complications from infection; in general, duration for a community/household exposure is 7 days from last known exposure and duration for an institutional outbreak is a minimum of 2 weeks and at least 1 week after the last identified case. See current guidelines for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34493538','lexi-content-ref-CDC.2','lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34493538','lexi-content-ref-CDC.2','lexi-content-ref-30834445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 3 to 8 months: Limited data available: Oral: 3 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34493538','lexi-content-ref-CDC.2','lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34493538','lexi-content-ref-CDC.2','lexi-content-ref-30834445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥9 months: Limited data available: Oral: 3.5 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34493538','lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34493538','lexi-content-ref-30834445'])">Ref</a></span>); some experts still recommend 3 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-30834445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-30834445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">≤15 kg: Oral: 30 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;15 kg to 23 kg: Oral: 45 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;23 kg to 40 kg: Oral: 60 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: Oral: 75 mg once daily.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51151022"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20397934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20397934'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis (IHD): Fixed dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">≤15 kg: 7.5 mg after each hemodialysis session.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;15 kg to ≤23 kg: 10 mg after each hemodialysis session.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;23 kg to ≤40 kg: 15 mg after each hemodialysis session.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;40 kg: 30 mg after each hemodialysis session.</p>
<p style="text-indent:-2em;margin-left:4em;">Prophylaxis: There are no pediatric specific recommendations; based on experience in adult patients, dosage adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51151023"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F55003686"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Oseltamivir commonly causes <b>nausea</b> and <b>vomiting </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25640810','lexi-content-ref-24811411','lexi-content-ref-29186364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25640810','lexi-content-ref-24811411','lexi-content-ref-29186364'])">Ref</a></span>). Most GI adverse reactions are transient and are unlikely to require discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10536125']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10536125'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20189775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20189775'])">Ref</a></span>); exact mechanism is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27364959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27364959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; most often within the first 2 days of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10536125']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10536125'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Increasing doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20189775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20189775'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Rare occurrences of neuropsychiatric events (including <b>confusion</b>, <b>delirium</b>, <b>hallucination</b>, and/or self-injury) with oseltamivir have been reported primarily in children and adolescents from postmarketing surveillance. Clinicians should note that influenza infection may also be associated with behavioral and neurologic changes, including cases resulting in fatal outcomes; these events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe influenza disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Direct causation has not been established and data are conflicting. Several recent studies have shown either no difference in the estimated incidence of life-threatening abnormal behavior or a lower estimated risk of severe neuropsychiatric events in patients who received neuraminidase inhibitors, including oseltamivir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29531106','lexi-content-ref-31996920','lexi-content-ref-26132729','lexi-content-ref-29273435','lexi-content-ref-26424023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29531106','lexi-content-ref-31996920','lexi-content-ref-26132729','lexi-content-ref-29273435','lexi-content-ref-26424023'])">Ref</a></span>); whereas others have continued to demonstrate an increased risk of psychiatric events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30418537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30418537'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Direct causation has not been established; exact mechanism is unknown, and effect may also be a result of the natural disease course of influenza (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28818475','lexi-content-ref-27364959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28818475','lexi-content-ref-27364959'])">Ref</a></span>). It is possible that inhibition of nicotinic acetylcholine receptors and monoamine oxidase-A receptors by oseltamivir is related to observed abnormal behaviors; action at NMDA and GABA receptors (similar to that which is seen with ketamine) or stimulation of D2 dopaminergic receptors may also be implicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27364959','lexi-content-ref-32905132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27364959','lexi-content-ref-32905132'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; reports of neuropsychiatric events often occur within 2 days of both the influenza diagnosis and the initiation of oseltamivir treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23054689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23054689'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i>
<b>Note: </b>Causality has not been established; therefore, risk factors listed below may reflect epidemiologic data as opposed to true risk factors.</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents 10 to 19 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26424023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26424023'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26424023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26424023'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F204084"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (2% to 16%)<span class="lexi-table-link-container"> (<a aria-label="Oseltamivir: Adverse Reaction: Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-oseltamivir-adverse-reaction-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-oseltamivir-adverse-reaction-vomiting')">table 1</a>)</span><span class="table-link" style="display:none;">Oseltamivir: Adverse Reaction: Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Oseltamivir: Adverse Reaction: Vomiting" frame="border" id="lexi-content-oseltamivir-adverse-reaction-vomiting" rules="all">
<caption style="text-align:center;">
<b>Oseltamivir: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oseltamivir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oseltamivir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 60 mg once daily for 10 days</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prophylaxis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 mg per kg twice daily for 5 days or weight-band dosing</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Treatment</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">859</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents &amp; adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg once daily for up to 6 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prophylaxis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,943</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,586</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents &amp; adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg twice daily for 5 days</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Treatment</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,646</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,977</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (adolescents and adults: 2% to 17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (adolescents and adults: 8% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Oseltamivir: Adverse Reaction: Nausea table link" class="lexi-table-link" data-table-id="lexi-content-oseltamivir-adverse-reaction-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-oseltamivir-adverse-reaction-nausea')">table 2</a>)</span><span class="table-link" style="display:none;">Oseltamivir: Adverse Reaction: Nausea</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Oseltamivir: Adverse Reaction: Nausea" frame="border" id="lexi-content-oseltamivir-adverse-reaction-nausea" rules="all">
<caption style="text-align:center;">
<b>Oseltamivir: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oseltamivir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oseltamivir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents &amp; adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg once daily for up to 6 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prophylaxis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,943</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,586</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents &amp; adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg twice daily for 5 days</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Treatment</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,646</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,977</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Pain (adolescents and adults: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (Karplus 2010), cardiac arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis, eczema, erythema multiforme, skin rash (Kaji 2005), Stevens-Johnson syndrome (Smith 2010), toxic epidermal necrolysis (Zuo 2019), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Exacerbation of diabetes mellitus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage (Fang 2018), hemorrhagic colitis (Nakagawa 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (Fang 2018), hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Hirschfeld 2008), facial edema, nonimmune anaphylaxis, swollen tongue (Kalsi 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal behavior (Chen 2019), agitation (Kohen 2007), anxiety, confusion (rare: &lt;1%) (Kohen 2007), delirium (rare: &lt;1%) (Kohen 2007), delusion (Chen 2019), hallucination (rare: &lt;1%) (Chen 2019, Nakamura 2010), hypothermia, impaired consciousness, nightmares, seizure</p></div>
<div class="block coi drugH1Div" id="F204096"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to oseltamivir or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F204081"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic impairment; safety and efficacy have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution; dosage adjustment is required for patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sorbitol: Oral suspension contains sorbitol (delivers ~2 g sorbitol per 75 mg dose) which is greater than the maximum daily limit for patients with hereditary fructose intolerance; may cause diarrhea and dyspepsia; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Oseltamivir is not a substitute for the influenza virus vaccine. It has not been shown to prevent primary or concomitant bacterial infections that may occur with influenza virus. Antiviral treatment should begin within 48 hours of symptom onset; however, the CDC recommends that treatment may still be beneficial and should be started in patients with severe, complicated or progressive illness, and in hospitalized patients if &gt;48 hours. Treatment should not be delayed while awaiting results of laboratory tests for influenza (CDC 2022a).</p></div>
<div class="block foc drugH1Div" id="F204091"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as phosphate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tamiflu: 30 mg, 45 mg, 75 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 45 mg, 75 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tamiflu: 6 mg/mL (60 mL) [contains saccharin sodium, sodium benzoate, sorbitol; tutti-frutti flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6 mg/mL (60 mL)</p></div>
<div class="block geq drugH1Div" id="F204077"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F204098"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Oseltamivir Phosphate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $5.27 - $14.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $5.27 - $14.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $5.27 - $15.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Tamiflu Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $16.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $16.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $18.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Oseltamivir Phosphate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg/mL (per mL): $0.88 - $2.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Tamiflu Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg/mL (per mL): $3.04</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867773"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as phosphate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tamiflu: 30 mg, 45 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tamiflu: 75 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 45 mg, 75 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tamiflu: 6 mg/mL (65 mL) [contains saccharin sodium, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6 mg/mL (65 mL)</p></div>
<div class="block adm drugH1Div" id="F5383845"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">May be administered without regard to meals; take with food to improve tolerance.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsules may be opened and mixed with sweetened liquid (eg, chocolate syrup, corn syrup, caramel topping, light brown sugar dissolved in water). Administer oral suspension using an oral dosing dispenser that measures the appropriate volume in milliliters; shake well before each use. When oral suspension is not available and/or age-appropriate strength of capsules are not available to mix with sweetened liquids, an extemporaneous preparation may be prepared (refer to “extemporaneously prepared” section of monograph for further details).</p>
<p style="text-indent:-2em;margin-left:2em;">Mechanically ventilated critically ill patients: May administer via naso- or orogastric (NG/OG) tube. Dissolve powder from capsules in 20 mL of sterile water and inject down the NG/OG tube; follow with a 10 mL sterile water flush (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18923671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18923671'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613480"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer with or without food; may decrease stomach upset if administered with food.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: May be opened and mixed with sweetened liquid (eg, chocolate syrup, corn syrup, caramel topping, light brown sugar [dissolved in water]). May be administered via naso- or orogastric tube in mechanically ventilated patients; for a 150 mg dose (in adults), dissolve powder from two 75 mg capsules in 20 mL of sterile water and inject down the NG/OG tube; follow with a 10 mL sterile water flush (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18923671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18923671'])">Ref</a></span>). However, a prospective cohort study in critically ill pediatric patients (n=11; age range: 8 months to 19 years) found the concentration of oseltamivir carboxylate (active metabolite) to be lower when administered by enteral tube compared to oral administration; clinical significance is unclear; closely monitor patient response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31738337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31738337'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: Shake suspension well before use; measure dose in an appropriately sized calibrated oral syringe that provides accurate measurement of prescribed dose.</p></div>
<div class="block use drugH1Div" id="F204092"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, seasonal, prophylaxis:</b> Prophylaxis of influenza (A or B) infection in patients ≥1 year of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, seasonal, treatment:</b> Treatment of uncomplicated acute illness due to influenza (A or B) infection in patients ≥2 weeks of age who have been symptomatic for ≤48 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not a substitute for annual influenza vaccination. Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir. Not recommended for patients with end-stage renal disease not undergoing dialysis.</p></div>
<div class="block off-label drugH1Div" id="F25860706"><span class="drugH1">Use: Off-Label: Adult</span><p>Influenza A, avian, postexposure prophylaxis; Influenza A, avian, treatment</p></div>
<div class="block mst drugH1Div" id="F204146"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tamiflu may be confused with Tambocor, Thera-Flu</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Oseltamivir (Tamiflu) oral suspension is available in a 6 mg/mL concentration. <b>Instructions to the patient should be provided based on these units of measure (ie, mL). When providing oseltamivir suspension, ensure the patient has an appropriately sized calibrated oral syringe that allows for accurate measurement of the prescribed dose.</b></p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">When commercially-prepared oseltamivir oral suspension is not available, an extemporaneously prepared suspension may be compounded to provide a 6 mg/mL concentration.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299796"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F204086"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: May increase the serum concentration of Oseltamivir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Management: Avoid use of fexinidazole with OAT1/3 substrates when possible. If combined, monitor for increased OAT1/3 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid administration of live influenza virus vaccine (LAIV) within 2 weeks before or 48 hours after administration of antiviral agents. Consider avoiding LAIV if peramivir was given within the last 5 days or baloxavir was given within the last 17 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase serum concentrations of the active metabolite(s) of Oseltamivir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F204099"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Oseltamivir phosphate and its active metabolite oseltamivir carboxylate cross the placenta (Meijer 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Based on multiple studies, the maternal use of oral oseltamivir is acceptable for use during pregnancy (CDC 2022a; CDC 2022e).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant and postpartum patients (≤2 weeks after delivery) have a higher risk for complications from untreated seasonal influenza, including preterm delivery, pneumonia, admission to a hospital or ICU, and maternal and fetal death. Underlying maternal medical conditions increase these risks (ACOG 2018; CDC 2022a). Treatment with oseltamivir prevents maternal respiratory failure and death when started &lt;3 days of the onset of illness; benefit is still obtained when started 3 to 4 days after onset in comparison to ≥5 days (CDC 2022a; CDC 2022e).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of oseltamivir may be altered (Beigi 2011; Greer 2011a; Pillai 2015). Dosing is the same as in nonpregnant patients (CDC 2022a; CDC 2022e). Higher doses may be needed in some patients; however, safety data for higher dosing during pregnancy are not available (CDC 2022e).</p>
<p style="text-indent:0em;margin-top:2em;">Oral oseltamivir is the preferred neuraminidase inhibitor for the treatment and prophylaxis of seasonal influenza during pregnancy. Pregnant patients with known or suspected influenza can be treated with antiviral medications, regardless of trimester, vaccination status, or laboratory test results. Postexposure antiviral prophylaxis may be considered for pregnant and postpartum patients (including following pregnancy loss) (ACOG 2018; CDC 2022a; CDC 2022e).</p>
<p style="text-indent:0em;margin-top:2em;">An algorithm is available for the treatment of pregnant patients with known or suspected seasonal influenza (ACOG 2018). Refer to the Centers for Disease Control and Prevention recommendations for treatment updates based on resistance patterns (ACOG 2018; CDC 2022a).</p></div>
<div class="block brc drugH1Div" id="F204100"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Oseltamivir and oseltamivir carboxylate are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of oseltamivir in breast milk are available from 2 studies:</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast milk was sampled following maternal administration of oral oseltamivir 75 mg twice daily for 5 days for the treatment of H5N1 influenza in 1 lactating patient at 9 months postpartum. Eleven breast milk samples were obtained over the dosing period. Using the maximum breast milk concentration of oseltamivir plus oseltamivir carboxylate (81.6 ng/mL), the authors of the study calculated the relative infant dose (RID) of oseltamivir to be 0.5% of the weight-adjusted maternal dose of 2.5 mg/kg/day, providing an estimated daily infant dose via breast milk of 0.012 mg/kg/day (Wentges-van Holthe 2008). In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">• A second study included 7 women given a single dose oseltamivir 75 mg immediately postpartum. Breast milk was collected for 24 hours after the dose. The maximum breast milk concentrations occurred at 3.4 ± 2.2 hours for oseltamivir and 18.9 ± 6.4 hours for oseltamivir carboxylate. The half-life of oseltamivir was ~4 hours in both the maternal serum and breast milk. Small amounts of oseltamivir carboxylate continued to be measurable in breast milk 24 hours after the single dose (~30 ng/mL) (Greer 2011b).</p>
<p style="text-indent:-2em;margin-left:4em;">• Adverse events following exposure to oseltamivir via breast milk are unlikely due to poor excretion into breast milk (CDC 2021b).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. However, breastfeeding does not need to be discontinued during oseltamivir treatment (IDSA [Uyeki 2019]). Due to limited excretion into breast milk, oseltamivir may be the preferred neuraminidase inhibitor for the treatment of seasonal influenza in patients who are breastfeeding. Infectious patients should take precautions to avoid influenza transmission to the breastfed infant. If the mother is too ill to breastfeed, expressed breast milk can be given to the infant by a healthy caregiver who does not have influenza (CDC 2021b).</p></div>
<div class="block dic drugH1Div" id="F204101"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take without regard to meals; take with food to improve tolerance.</p></div>
<div class="block mop drugH1Div" id="F3467518"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs or symptoms of unusual behavior, including attempts at self-injury, confusion, and/or delirium</p>
<p style="text-indent:-2em;margin-left:2em;">Critically ill patients: Repeat rRT-PCR or viral culture may help to determine on-going viral replication</p></div>
<div class="block pha drugH1Div" id="F204080"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Oseltamivir, a prodrug, is hydrolyzed to the active form, oseltamivir carboxylate (OC). OC inhibits influenza virus neuraminidase, an enzyme known to cleave the budding viral progeny from its cellular envelope attachment point (neuraminic acid) just prior to release.</p></div>
<div class="block phk drugH1Div" id="F204095"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Concurrent use of extracorporeal membrane oxygenation (ECMO): When used alone, ECMO has been shown not to impact oseltamivir carboxylate C<sub>max</sub> and AUC in 2 small studies (Lemaitre 2012; Mulla 2013). Pharmacokinetics in children ≥12 years and adolescents are similar to adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Oseltamivir carboxylate:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients (Kimberlin 2013):</p>
<p style="text-indent:-2em;margin-left:6em;">≤2 months: Median: 5.8 L/kg; Range: 2.97 to 44.91 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">3 to 5 months: Median: 10.4 L/kg; Range: 4.03 to 13.94 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">6 to 8 months: Median: 10.19 L/kg; Range: 1.39 to 107.59 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">9 to 11 months:</p>
<p style="text-indent:-2em;margin-left:8em;">3 mg/kg: Median: 15.13 L/kg; Range: 5.46 to 95.3 L/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">3.5 mg/kg: Median: 10.41 L/kg; Range: 7.04 to 21.56 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">12 to 23 months:</p>
<p style="text-indent:-2em;margin-left:8em;">3.5 mg/kg: Median: 24.36 L/kg; Range: 8.97 to 47.37 L/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">30 mg (fixed dose): Median: 13.92 L/kg; Range: 5.89 to 53.31 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 23 to 26 L; may be significantly increased in patients receiving ECMO (Lemaitre 2012; Mulla 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: Oseltamivir carboxylate: 3%; Oseltamivir: 42%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (90%) to oseltamivir carboxylate; neither the parent drug nor active metabolite has any effect on the cytochrome P450 system.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 75% as oseltamivir carboxylate.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients (Kimberlin 2013): Oseltamivir carboxylate:</p>
<p style="text-indent:-2em;margin-left:6em;">≤2 months: Median: 6.64 hours; Range: 4.65 to 28.71 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">3 to 5 months: Median: 9.09 hours; Range: 6.25 to 19 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">6 to 8 months: Median:10.29 hours; Range: 1.02 to 78.26 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">9 to 11 months:</p>
<p style="text-indent:-2em;margin-left:8em;">3 mg/kg: Median: 11.13 hours; Range: 5.4 to 51.86 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">3.5 mg/kg: Median: 14.56 hours; Range: 7.22 to 25.67 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">12 to 23 months:</p>
<p style="text-indent:-2em;margin-left:8em;">3.5 mg/kg: Median: 14.82 hours; Range: 8.13 to 20.16 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">30 mg (fixed dose): Median: 7.98 hours; Range: 4.49 to 17.11 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Oseltamivir: 1 to 3 hours; Oseltamivir carboxylate: 6 to 10 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&gt;99% as oseltamivir carboxylate); feces (&lt;20%).</p></div>
<div class="block phksp drugH1Div" id="F51160059"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Exposure to the active metabolite is inversely proportional to declining renal function. In continuous ambulatory peritoneal dialysis (CAPD) patients, the peak concentration of the active metabolite following a single 30 mg oseltamivir dose or once-weekly oseltamivir was 3-fold higher than in patients with normal renal function receiving the approved adult dose. Administration of 30 mg once weekly to CAPD patients resulted in plasma concentrations of active metabolite comparable to patients with normal renal function receiving the approved adult doses.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Preterm neonates have decreased clearance of oseltamivir due to immature renal function (Acosta 2010). Exposure to active metabolite (oseltamivir carboxylate) is more variable in neonates and young infants (&lt;9 months of age) due to maturation and greater variability of the carboxylesterase HCE-1; formation of active metabolite may be delayed, but overall exposure is similar. Clearance of the active metabolite increases throughout infancy. Exposures in these patients may be lower for similar mg/kg doses, particularly beginning at age 9 months (Kimberlin 2013). Children ≤12 years of age clear the prodrug and active metabolite faster than adults, resulting in a lower exposure with a given mg/kg dose. The pharmacokinetics of the prodrug in patients &gt;12 years of age are similar to adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Exposure to the active metabolite at steady state was 25% to 35% higher in elderly patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F204102"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Seltaflu | Tamiflu</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Agripan | Agucort | Fada oseltamivir | Oseltamivir Elea | Oseltamivir Finadiet | Oseltamivir Northia | Oseltamivir Sidus | Tamiflu | Veltamir</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Oseltamivir lupin | Talminex | Tamiflu</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Flutavir | Oselta</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Oseltamivir abr | Tamiflu</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Farmanguinhos oseltamivir | Fosfato de oseltamivir | Oselflu | Tamiflu</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Euvirax | Tamiflu</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Oltamir | Tamiflu | Tazamir</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Tamiflu</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Oseltam | Oseltamivir | Ribax | Tamiflu</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fluhalt | Oseltamivir | Tamiflu</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Segosana | Tamiflu</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu | Taminil | Taminil n</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Oseltamivir zentiva | Tamiflu</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Oseltamivir | Tamiflu</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Eraflu | Tamiflu</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Segosana | Tamiflu</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Antiflu | Flucover | Fluvir | Olsivir | Oltavir | Oselow</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Flutan</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Fluvir | Tamiflu</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Oseltamivir | Tamiflu</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A flu | Ahngook oseltamivir | Anaflu | Anyflu | Ausflu | Bcelflu | Boryung flu | Boryung tami | Byaflu | Callmeflu | Comyflu | Daewoo flu | Daewoongbio flu | Dongkoo oseltamivir phosphate | Dongwha flu en | Easy flu | Easyflu | Enpiflu | Flu bm | Flucle | Fluone | Flurex | Flutam | Fluvir | Genuone oseltami | Genupharma tamiro | Hanaflu | Hanlim oseltamivir phosphate | Hanmi flu | Hanmi flu s | K flu | Kolmar Oseltami | Mediflu | New flu | Newraflu | Nex flu | Od flu | Oseltami | Oseltawon | Osul m | Penflu | Pharvi flu | Phaviflu | Phenflu | Pluta | Praflu | Reyon oseltamivir phosphate | Samjinflu | Samsung oselta | Selta flu | Seltaflu | Shinpoong flu | Tamflu | Tami infle | Tami k | Tami one | Tamiflu | Tamifos | Tamiful m | Tamilex | Taminewra | Tamio | Tamipro | Tamir | Tamiselva | Tamiselvir | Tamituss | Tamivict | Tamivir | Unitamivir | Utaflu | Viselflu | Yuhan n flu | Yungjin oseltamivir | Yuyu tami</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Oselta | Tamiflu</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Flumivir | Genflu | Tamiflu | Viriflu</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Segosana | Tamiflu</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Segosana | Tamiflu</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Genflu | Tamiflu</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Estranim | Gremiltal | Ineolflu | Lirisek | Oseltamivir | Seltaferon | Tamiflu | Taviden flu | Wernicros</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Antiflu | Fluhalt | Natflu | Omiflu | Oseltamivir | Osmivir | Tamiflu</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Tamiflu</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Roxid | Tamiflu</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Oseltamivir Rite med | Tamiflu</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Flimivir | Ostavir flu | Pronto | Tamiflu</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Segosana | Tamiflu</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Tamiflu</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Biocid | Disemid | Euvirax | Hontix | Imuclone | Intenza | Novo grip | Oselta | Oseltamivir | Oseltamivir cipla | Oseltamivir dallas | Oseltamivir promepar | Oseltamivir vivele | Stoper | Tamiflu</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Segosana | Tamiflu</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Griptera | Nomides | Oseltamivir | Oseltamivir akrikhin | Oseltamivir avexima | Oseltamivir nativ | Seltaivir | Seltavir | Tamiflu</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Oselta | Tamiflu</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ebilfumin | Tamiflu | Tamiflu Ebb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Starflu | Tamiflu</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">A flu | Tamiflu</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Adyflu | Saiflu | Tamiflu</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cyovel | Enfluvir | Enzaflu | Novavir | Oseflu | Oselmir | Seltavir | Tamiflu</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Eraflu | Oseltamivir | Tamiflu</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Flucap | Natflu | Oseltamivir | Seltavir | Tamiflu | Tamivir</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Agucort | Oselta | Oseltamivir | Oseltamivir Lazar | Serviflu | Tamiflu | Tamiflu pediatrico</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aviflu | Cipla oseltamivir | Fluvir | Macselta | Oselflu | Oselow | Oseltamivir adco | Tamiflu | Tamygen</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Tamiflu</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-20594104">
<a name="20594104"></a>Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. <i>J Infect Dis</i>. 2010;202(4):563-566. doi:10.1086/654930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/20594104/pubmed" id="20594104" target="_blank">20594104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30247362">
<a name="30247362"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 753: assessment and treatment of pregnant women with suspected or confirmed influenza. <i>Obstet Gynecol</i>. 2018;132(4):e169-e173. doi:10.1097/AOG.0000000000002872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/30247362/pubmed" id="30247362" target="_blank">30247362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34493538">
<a name="34493538"></a>American Academy of Pediatrics (AAP) Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2021-2022. <i>Pediatrics</i>. Published online September 7, 2021. doi:10.1542/peds.2021-053745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/34493538/pubmed" id="34493538" target="_blank">34493538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31477606">
<a name="31477606"></a>American Academy of Pediatrics Committee on Infectious Diseases (AAP). Recommendations for prevention and control of influenza in children, 2022-2023. <i>Pediatrics</i>. 2022;150(4):e2022059274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/31477606/pubmed" id="31477606" target="_blank">31477606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24294283">
<a name="24294283"></a>Aoki FY, Allen UD, Stiver HG, Evans GA. The use of antiviral drugs for influenza: guidance for practitioners 2012/2013. <i>Can J Infect Dis Med Microbiol</i>. 2012;23(4):e79-e92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/24294283/pubmed" id="24294283" target="_blank">24294283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20159892">
<a name="20159892"></a>Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. <i>CMAJ</i>. 2010;182(4):357-363. doi: 10.1503/cmaj.092127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/20159892/pubmed" id="20159892" target="_blank">20159892</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Beigi RH, Han K, Venkataramanan R, et al; Obstetric-Fetal Pharmacology Research Units Network. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. <i>Am J Obstet Gynecol</i>. 2011;204(6 suppl 1):S84-S88. doi:10.1016/j.ajog.2011.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/21492826/pubmed" id="21492826" target="_blank">21492826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin</i>
<i>Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2016a">
<a name="CDC.2016a"></a>Centers for Disease Control and Prevention (CDC). Interim guidance on influenza antiviral chemoprophylaxis of persons exposed to birds with avian influenza A viruses associated with severe human disease or with the potential to cause severe human disease. Centers for Disease Control and Prevention website. <a href="https://www.cdc.gov/flu/avianflu/guidance-exposed-persons.htm" target="_blank">https://www.cdc.gov/flu/avianflu/guidance-exposed-persons.htm</a>. Updated March 24, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2016b">
<a name="CDC.2016b"></a>Centers for Disease Control and Prevention (CDC). Interim guidance on the use of antiviral medications for treatment of human infections with novel influenza A viruses associated with severe human disease. Centers for Disease Control and Prevention website. <a href="https://www.cdc.gov/flu/avianflu/novel-av-treatment-guidance.htm" target="_blank">https://www.cdc.gov/flu/avianflu/novel-av-treatment-guidance.htm</a>. Updated March 23, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2017">
<a name="CDC.2017"></a>Centers for Disease Control and Prevention (CDC). Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses associated with severe human disease and on the use of antiviral medications for chemoprophylaxis. <a href="https://www.cdc.gov/flu/avianflu/novel-av-chemoprophylaxis-guidance.htm" target="_blank">https://www.cdc.gov/flu/avianflu/novel-av-chemoprophylaxis-guidance.htm</a>. Updated March 25, 2022d.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Published September 9, 2022a. Accessed September 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Published September 22, 2021a. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. <a href="https://www.cdc.gov/flu/professionals/antivirals/avrec_ob.htm" target="_blank">https://www.cdc.gov/flu/professionals/antivirals/avrec_ob.htm</a>. Published September 15, 2022e. Accessed September 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.4">
<a name="CDC.4"></a>Centers for Disease Control and Prevention (CDC). Breastfeeding. Influenza (Flu). <a href="https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/influenza.html" target="_blank">https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/influenza.html</a>. Published January 12, 2021b. Accessed on January 19, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26810861">
<a name="26810861"></a>Chairat K, Jittamala P, Hanpithakpong W, et al. Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. <i>Br J Clin Pharmacol</i>. 2016;81(6):1103-1112. doi:10.1111/bcp.12892<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/26810861/pubmed" id="26810861" target="_blank">26810861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30832611">
<a name="30832611"></a>Chen R, Fang Z, Huang Y. Neuropsychiatric events in an adult patient with influenza a (H3N2) treated with oseltamivir (Tamiflu): a case report. <i>BMC Infect Dis</i>. 2019;19(1):224. doi:10.1186/s12879-019-3827-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/30832611/pubmed" id="30832611" target="_blank">30832611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25640810">
<a name="25640810"></a>Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. <i>Lancet</i>. 2015;385(9979):1729-1737. doi:10.1016/S0140-6736(14)62449-1 [Erratum in: <i>Lancet</i>. 2015;385(9979):1728. Erratum in: <i>Lancet</i>. 2015;385(9979):1728.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/25640810/pubmed" id="25640810" target="_blank">25640810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20625883">
<a name="20625883"></a>Dolley-Hitze T, Verdier MC, Tribut O, Le Tulzo Y, Marqué S. Oseltamivir dose adjustment in an H1N1 patient requiring haemodialysis. <i>Intensive Care Med</i>. 2010;36(9):1618-1619. doi:10.1007/s00134-010-1943-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/20625883/pubmed" id="20625883" target="_blank">20625883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20189775">
<a name="20189775"></a>Dutkowski R, Smith JR, Davies BE. Safety and pharmacokinetics of oseltamivir at standard and high dosages. <i>Int J Antimicrob Agents</i>. 2010;35(5):461-467. doi:10.1016/j.ijantimicag.2009.12.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/20189775/pubmed" id="20189775" target="_blank">20189775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23208833">
<a name="23208833"></a>Eyler RF, Heung M, Pleva M, et al. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. <i>Pharmacotherapy.</i> 2012;32(12):1061-1069.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/23208833/pubmed" id="23208833" target="_blank">23208833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30235756">
<a name="30235756"></a>Fang S, Qi L, Zhou N, Li C. Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report. <i>Medicine (Baltimore)</i>. 2018;97(38):e12497. doi:10.1097/MD.0000000000012497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/30235756/pubmed" id="30235756" target="_blank">30235756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28818475">
<a name="28818475"></a>Fukushima W, Ozasa K, Okumura A, et al. Oseltamivir use and severe abnormal behavior in Japanese children and adolescents with influenza: Is a self-controlled case series study applicable? <i>Vaccine</i>. 2017;35(36):4817-4824. doi:10.1016/j.vaccine.2017.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/28818475/pubmed" id="28818475" target="_blank">28818475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21492824">
<a name="21492824"></a>Greer LG, Leff RD, Rogers VL, et al. Pharmacokinetics of oseltamivir according to trimester of pregnancy. <i>Am J Obstet Gynecol</i>. 2011a;204(6 suppl 1):S89-S93. doi:10.1016/j.ajog.2011.03.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/21492824/pubmed" id="21492824" target="_blank">21492824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21457910">
<a name="21457910"></a>Greer LG, Leff RD, Rogers VL, et al. Pharmacokinetics of oseltamivir in breast milk and maternal plasma. <i>Am J Obstet Gynecol</i>. 2011b;204(6):524.e1-e4. doi:10.1016/j.ajog.2011.01.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/21457910/pubmed" id="21457910" target="_blank">21457910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30141464">
<a name="30141464"></a>Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. <i>MMWR Recomm Rep</i>. 2018;67(3):1-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/30141464/pubmed" id="30141464" target="_blank">30141464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27364959">
<a name="27364959"></a>Hama R, Bennett CL. The mechanisms of sudden-onset type adverse reactions to oseltamivir. <i>Acta Neurol Scand</i>. 2017;135(2):148-160. doi:10.1111/ane.12629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/27364959/pubmed" id="27364959" target="_blank">27364959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19281331">
<a name="19281331"></a>Harper SA, Bradley JS, Englund JA, et al, "Seasonal Influenza in Adults and Children - Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America," <i>Clin Infect Dis</i>, 2009, 48(8):1003-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/19281331/pubmed" id="19281331" target="_blank">19281331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29531106">
<a name="29531106"></a>Harrington R, Adimadhyam S, Lee TA, Schumock GT, Antoon JW. The relationship between oseltamivir and suicide in pediatric patients. <i>Ann Fam Med</i>. 2018;16(2):145-148. doi:10.1370/afm.2183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/29531106/pubmed" id="29531106" target="_blank">29531106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10536125">
<a name="10536125"></a>Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. <i>N Engl J Med</i>. 1999;341(18):1336-1343. doi:10.1056/NEJM199910283411802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/10536125/pubmed" id="10536125" target="_blank">10536125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18186817">
<a name="18186817"></a>Hirschfeld G, Weber L, Renkl A, Scharffetter-Kochanek K, Weiss JM. Anaphylaxis after oseltamivir (Tamiflu) therapy in a patient with sensitization to star anise and celery-carrot-mugwort-spice syndrome. <i>Allergy</i>. 2008;63(2):243-244. doi:10.1111/j.1398-9995.2007.01572.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/18186817/pubmed" id="18186817" target="_blank">18186817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31996920">
<a name="31996920"></a>Huh K, Kang M, Shin DH, Hong J, Jung J. Oseltamivir and the risk of neuropsychiatric events: a national, population-based study. <i>Clin Infect Dis</i>. 2020:ciaa055. doi:10.1093/cid/ciaa055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/31996920/pubmed" id="31996920" target="_blank">31996920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24811411">
<a name="24811411"></a>Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. <i>BMJ</i>. 2014;348:g2545. doi:10.1136/bmj.g2545<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/24811411/pubmed" id="24811411" target="_blank">24811411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24366750">
<a name="24366750"></a>Jittamala P, Pukrittayakamee S, Tarning J, et al. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. <i>Antimicrob Agents Chemother</i>. 2014;58(3):1615-1621. doi:10.1128/AAC.01786-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/24366750/pubmed" id="24366750" target="_blank">24366750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32947554">
<a name="32947554"></a>Jones TE. Oseltamivir-current dosing recommendations reduce the therapeutic benefit in patients with mild to moderate renal function and/or large body mass: a review of the literature with recommendations to optimize dosing, including the use of therapeutic drug monitoring. <i>Ther Drug Monit</i>. 2021;43(1):103-107. doi:10.1097/FTD.0000000000000797<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/32947554/pubmed" id="32947554" target="_blank">32947554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15729487">
<a name="15729487"></a>Kaji M, Fukuda T, Tanaka M, Aizawa H. A side effect of neuraminidase inhibitor in a patient with liver cirrhosis. <i>J Infect Chemother</i>. 2005;11(1):41-43. doi:10.1007/s10156-004-0358-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/15729487/pubmed" id="15729487" target="_blank">15729487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22687684">
<a name="22687684"></a>Kalsi T, Stevenson J, Wade P, Kinirons M. Tongue swelling in association with oseltamivir (Tamiflu). <i>BMJ Case Rep</i>. 2011;2011:bcr0620114396. doi:10.1136/bcr.06.2011.4396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/22687684/pubmed" id="22687684" target="_blank">22687684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27137141">
<a name="27137141"></a>Kamal MA, Brennan BJ, Subramoney V, et al. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment. <i>Clin Pharmacol Drug Dev.</i> 2015a;4(5):326-336. doi:10.1002/cpdd.203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/27137141/pubmed" id="27137141" target="_blank">27137141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26282419">
<a name="26282419"></a>Kamal MA, Lien KY, Robson R, et al. Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach. <i>Antimicrob Agents Chemother</i>. 2015b;59(11):6774-6781. doi:10.1128/AAC.01024-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/26282419/pubmed" id="26282419" target="_blank">26282419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30418537">
<a name="30418537"></a>Kang HR, Lee EK, Kim WJ, Shin JY. Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study. <i>J Antimicrob Chemother</i>. 2019;74(2):453-461. doi:10.1093/jac/dky445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/30418537/pubmed" id="30418537" target="_blank">30418537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20615742">
<a name="20615742"></a>Karplus R, Sanset S, Zaidenstein R, Schneider D, Berkovitch M. Suspected oseltamivir-induced bradycardia. <i>Int J Infect Dis</i>. 2010;14(suppl 3):e374-e375. doi:10.1016/j.ijid.2010.03.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/20615742/pubmed" id="20615742" target="_blank">20615742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23230059">
<a name="23230059"></a>Kimberlin DW, Acosta EP, Prichard MN, et al. Oseltamivir pharmacokinetics, dosing, and resistance among children aged &lt;2 years with influenza. <i>J Infect Dis</i>. 2013;207(5):709-720.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/23230059/pubmed" id="23230059" target="_blank">23230059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17721896">
<a name="17721896"></a>Kohen I. Oseltamivir-induced delirium in a geriatric patient. <i>Int J Geriatr Psychiatry</i>. 2007;22(9):935-936. doi:10.1002/gps.1838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/17721896/pubmed" id="17721896" target="_blank">17721896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24046309">
<a name="24046309"></a>Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza A and B infections. <i>Clin Infect Dis</i>. 2013;57(11):1511-1519. doi: 10.1093/cid/cit597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/24046309/pubmed" id="24046309" target="_blank">24046309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354159">
<a name="22354159"></a>Lemaitre F, Luyt C, Roullet-Renoleau F, et al. Impact of Extracorporeal Membrane Oxygenation and Continuous Venovenous Hemodiafiltration on the Pharmacokinetics of Oseltamivir Carboxylate in Critically Ill Patients With Pandemic (H1N1) Influenza. <i>Ther Drug Monit.</i> 2012;34:171-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/22354159/pubmed" id="22354159" target="_blank">22354159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29186364">
<a name="29186364"></a>Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and safety of oseltamivir in children: Systematic review and individual patient data meta-analysis of randomized controlled trials. <i>Clin Infect Dis</i>. 2018;66(10):1492-1500. doi:10.1093/cid/cix1040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/29186364/pubmed" id="29186364" target="_blank">29186364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22460968">
<a name="22460968"></a>Meijer WJ, Bruinse HW, van den Broek MP, Kromdijk W, Wensing AM. Oseltamivir and its active metabolite cross the placenta at significant levels. <i>Clin Infect Dis</i>. 2012;54(11):1676-1677.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/22460968 /pubmed" id="22460968 " target="_blank">22460968 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23362894">
<a name="23362894"></a>Mulla H, Peek GJ, Harvey C, et al. Oseltamivir Pharmacokinetics in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation Support. <i>Anaesth Intensive Care.</i> 2013;41(1):66-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/23362894/pubmed" id="23362894" target="_blank">23362894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21837605">
<a name="21837605"></a>Nakagawa Y, Nagai T, Okawara H, et al. Acute hemorrhagic colitis induced by the oral administration of oseltamivir used for influenza A treatment. <i>Endoscopy</i>. 2011;(43 suppl 2) UCTN:E261. doi:10.1055/s-0030-1256524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/21837605/pubmed" id="21837605" target="_blank">21837605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20192728">
<a name="20192728"></a>Nakamura K, Schwartz BS, Lindegårdh N, Keh C, Guglielmo BJ. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. <i>Clin Infect Dis</i>. 2010;50(7):e47-e49. doi:10.1086/651166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/20192728/pubmed" id="20192728" target="_blank">20192728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26132729">
<a name="26132729"></a>Nakamura Y, Sugawara T, Ohkusa Y, et al. Life-threatening abnormal behavior Incidence in 10-19 year old patients administered neuraminidase inhibitors. <i>PLoS One</i>. 2015;10(7):e0129712. doi:10.1371/journal.pone.0129712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/26132729/pubmed" id="26132729" target="_blank">26132729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29273435">
<a name="29273435"></a>Nakamura Y, Sugawara T, Ohkusa Y, et al. Severe abnormal behavior incidence after administration of neuraminidase inhibitors using the national database of medical claims. <i>J Infect Chemother</i>. 2018;24(3):177-181. doi:10.1016/j.jiac.2017.10.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/29273435/pubmed" id="29273435" target="_blank">29273435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oseltamivir.1">
<a name="Oseltamivir.1"></a>Oseltamivir [prescribing information]. Morristown, NJ: Alvogen, Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21930881">
<a name="21930881"></a>Pai MP, Lodise TP Jr. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. <i>Antimicrob Agents Chemother</i>. 2011;55(12):5640-5645. doi:10.1128/AAC.00422-11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/21930881/pubmed" id="21930881" target="_blank">21930881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25289522">
<a name="25289522"></a>Patel K, Rayner CR, Giraudon M, et al. Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis. <i>Brit J Clin Pharmacol.</i> 2015;79(4):624-635. doi:10.1111/bcp.12526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/25289522/pubmed" id="25289522" target="_blank">25289522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26040405">
<a name="26040405"></a>Pillai VC, Han K, Beigi RH, et al. Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. <i>Br J Clin Pharmacol</i>. 2015;80(5):1042-1050. doi:10.1111/bcp.12691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/26040405/pubmed" id="26040405" target="_blank">26040405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16799169">
<a name="16799169"></a>Robson R, Buttimore A, Lynn K, Brewster M, Ward P. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. <i>Nephrol Dial Transplant</i>. 2006;21(9):2556-2562. doi:10.1093/ndt/gfl267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/16799169/pubmed" id="16799169" target="_blank">16799169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20397934">
<a name="20397934"></a>Schreuder MF, van der Flier M, Knops NB, et al. Oseltamivir dosing in children undergoing hemodialysis. <i>Clin Infect Dis.</i> 2010;50(10):1427-1428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/20397934/pubmed" id="20397934" target="_blank">20397934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20132714">
<a name="20132714"></a>Smith EV, Pynn MC, Blackford S, Leopold DJ. Stevens-Johnson syndrome secondary to oseltamivir (Tamiflu). <i>Br J Gen Pract</i>. 2010;60(571):133-134. doi:10.3399/bjgp10X483292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/20132714/pubmed" id="20132714" target="_blank">20132714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23723457">
<a name="23723457"></a>South East Asia Infectious Disease Clinical Research Network (SEAICRN). Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. <i>BMJ</i>. 2013;346:f3039. doi: 10.1136/bmj.f3039.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/23723457/pubmed" id="23723457" target="_blank">23723457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tamiflu.2019.08">
<a name="Tamiflu.2019.08"></a>Tamiflu (oseltamivir) [prescribing information]. South San Francisco, CA: Genentech, Inc; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tamiflu.2018.12">
<a name="Tamiflu.2018.12"></a>Tamiflu (oseltamivir) [prescribing information]. South San Francisco, CA: Genentech, Inc; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tamiflu.2020.02">
<a name="Tamiflu.2020.02"></a>Tamiflu (oseltamivir) [product monograph]. Mississauga, Ontario, Canada: Hoffman-La Roche Limited; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31738337">
<a name="31738337"></a>Tang Girdwood SC, Mizuno T, Krallman KA, et al. Route of oseltamivir administration affects metabolite concentrations in critically ill children. <i>Pediatr Infect Dis J</i>. 2019;38(12):1224-1227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/31738337/pubmed" id="31738337" target="_blank">31738337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18923671">
<a name="18923671"></a>Taylor WRJ, Thinh BN, Anh GT, et al. Oseltamivir is Adequately Absorbed Following Nasogastric Administration to Adult Patients With Severe H5N1 Influenza. <i>PLoS One.</i> 2008;3(10):e3410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/18923671/pubmed" id="18923671" target="_blank">18923671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21700623">
<a name="21700623"></a>Thorne-Humphrey LM, Goralski KB, Slayter KL, Hatchette TF, Johnston BL, McNeil SA; 2009 OPTIMO Study Group. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). <i>J Antimicrob Chemother</i>. 2011;66(9):2083-2091. doi:10.1093/jac/dkr257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/21700623/pubmed" id="21700623" target="_blank">21700623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23054689">
<a name="23054689"></a>Toovey S, Prinssen EP, Rayner CR, et al. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. <i>Adv Ther</i>. 2012;29(10):826-848. doi:10.1007/s12325-012-0050-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/23054689/pubmed" id="23054689" target="_blank">23054689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin</i>
<i>Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26424023">
<a name="26424023"></a>Ueda N, Umetsu R, Abe J, et al. Analysis of neuropsychiatric adverse events in patients treated with oseltamivir in spontaneous adverse event reports. <i>Biol Pharm Bull</i>. 2015;38(10):1638-1644. doi:10.1248/bpb.b15-00253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/26424023/pubmed" id="26424023" target="_blank">26424023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30834445">
<a name="30834445"></a>Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. <i>Clin Infect Dis</i>. 2019;68(6):895-902. doi:10.1093/cid/ciy874.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/30834445/pubmed" id="30834445" target="_blank">30834445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29648602">
<a name="29648602"></a>Wang Y, Guo Q, Yan Z, et al; CAP-China Network. Factors associated with prolonged viral shedding in patients with avian influenza A(H7N9) virus infection.<i> J Infect Dis</i>. 2018;217(11):1708-1717. doi: 10.1093/infdis/jiy115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/29648602/pubmed" id="29648602" target="_blank">29648602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18243025">
<a name="18243025"></a>Wentges-van Holthe N, van Eijkeren M, van der Laan JW. Oseltamivir and breastfeeding. <i>Int J Infect Dis</i>. 2008;12(4):451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/18243025/pubmed" id="18243025" target="_blank">18243025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zachary.2019">
<a name="Zachary.2019"></a>Zachary KC. Seasonal influenza in adults: Role of antiviral prophylaxis for prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32905132">
<a name="32905132"></a>Zareifopoulos N, Lagadinou M, Karela A, Kyriakopoulou O, Velissaris D. Neuropsychiatric effects of antiviral drugs. <i>Cureus</i>. 2020;12(8):e9536. doi:10.7759/cureus.9536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/32905132/pubmed" id="32905132" target="_blank">32905132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31083216">
<a name="31083216"></a>Zuo W, Wen LP, Li J, Mei D, Fu Q, Zhang B. Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report. <i>Medicine (Baltimore)</i>. 2019;98(19):e15553. doi:10.1097/MD.0000000000015553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/31083216/pubmed" id="31083216" target="_blank">31083216</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9460 Version 428.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
